American Century Companies Inc. Boosts Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

American Century Companies Inc. grew its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 418.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 862,365 shares of the company's stock after buying an additional 695,932 shares during the quarter. American Century Companies Inc. owned approximately 0.10% of Dr. Reddy's Laboratories worth $13,617,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in RDY. Summit Global Investments increased its holdings in Dr. Reddy's Laboratories by 404.7% in the fourth quarter. Summit Global Investments now owns 141,902 shares of the company's stock worth $2,241,000 after purchasing an additional 113,785 shares in the last quarter. Aikya Investment Management Ltd lifted its position in shares of Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after buying an additional 4,523,303 shares in the last quarter. PDS Planning Inc grew its stake in Dr. Reddy's Laboratories by 389.3% in the 4th quarter. PDS Planning Inc now owns 32,254 shares of the company's stock valued at $509,000 after purchasing an additional 25,662 shares during the period. Signaturefd LLC increased its holdings in Dr. Reddy's Laboratories by 442.1% during the fourth quarter. Signaturefd LLC now owns 138,950 shares of the company's stock worth $2,194,000 after buying an additional 113,319 shares during the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Dr. Reddy's Laboratories by 399.5% in the 4th quarter. Parallel Advisors LLC now owns 72,790 shares of the company's stock worth $1,149,000 after purchasing an additional 58,218 shares during the period. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Trading Down 6.6 %

Shares of RDY stock traded down $0.87 during trading hours on Friday, reaching $12.37. The company's stock had a trading volume of 3,932,444 shares, compared to its average volume of 1,348,794. The firm's fifty day simple moving average is $13.33 and its 200 day simple moving average is $14.49. Dr. Reddy's Laboratories Limited has a one year low of $12.36 and a one year high of $16.89. The stock has a market capitalization of $10.32 billion, a P/E ratio of 19.69 and a beta of 0.51. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Nomura lowered Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.